63536 Old Deschutes Rd, Bend, OR 97701 • 5413831518
Corvallis, OR
Galata, MT
Work
Company:
Thermo fisher scientific
2017
Position:
Gvp, head of strategy
Education
Degree:
Doctorates, Doctor of Philosophy
School / High School:
Oregon State University
1992 to 1997
Skills
Pharmaceutical Industry • Technology Transfer • R&D • Biotechnology • Gmp • Drug Development • Fda • Life Sciences • Drug Discovery • Chemistry • Lifesciences • Analytical Chemistry • Validation • Manufacturing • Product Development • Business Strategy
Industries
Pharmaceuticals
Us Patents
Pharmaceutical Compositions Of Cholesteryl Ester Transfer Protein Inhibitors
Marshall D. Crew - Bend OR, US William J. Curatolo - Niantic CT, US Dwayne T. Friesen - Bend OR, US Michael Jon Gumkowski - Old Lyme CT, US Douglas A. Lorenz - Bend OR, US James A. S. Nightingale - Bend OR, US Roger B. Ruggeri - Waterford CT, US Ravi M. Shanker - Groton CT, US
Assignee:
Pfizer Inc - New York NY
International Classification:
A61K 9/14 A61K 31/47
US Classification:
424488, 514313
Abstract:
A pharmaceutical composition comprises a solid amorphous dispersion of a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer.
Pharmaceutical Compositions Of A Sparingly Soluble Glycogen Phosphorylase Inhibitor
Marshall D. Crew - Bend OR, US Dwayne T. Friesen - Bend OR, US Bruno C. Hancock - North Stonington CT, US Chris Macri - Belle Mead NJ, US James A. S. Nightingale - Bend OR, US Ravi M. Shankar - Groton CT, US
Assignee:
Pfizer Inc - New York NY
International Classification:
A61K 9/14 A61K 9/16 A61K 9/50
US Classification:
424489, 424497, 424498
Abstract:
Pharmaceutical compositions of a particularly effective sparingly soluble glycogen phosphorylase inhibitor are disclosed, as well as methods of making such compositions and dosage forms from such compositions.
Extrusion Process For Forming Chemically Stable Drug Multiparticulates
Roderick J. Ray - Bend OR, US Leah E. Appel - Bend OR, US David D. Newbold - Bend OR, US Dwayne T. Friesen - Bend OR, US Scott B. McCray - Bend OR, US David K. Lyon - Bend OR, US James B. West - Bend OR, US Marshall D. Crew - Bend OR, US Joshua R. Shockey - Bend OR, US
Assignee:
Pfizer Inc. - New York NY
International Classification:
B29B 9/00
US Classification:
264 5, 264 8, 264 9, 264 10, 264 11
Abstract:
Reduced levels of drug degradation in drug-containing multiparticulates are obtained by an extrusion/melt-congeal process.
Multiparticulate Compositions With Improved Stability
Roderick J. Ray - Bend OR, US Leah E. Appel - Bend OR, US Dwayne Thomas Friesen - Bend OR, US Marshall D. Crew - Bend OR, US Joshua R. Shockey - Bend OR, US
Assignee:
Pfizer, Inc. - New York NY
International Classification:
A61K 9/14
US Classification:
424489
Abstract:
A process is described for producing drug-containing multiparticulates with improved stability, characterized by an improvement in one or more of chemical stability, physical stability, or dissolution stability.
Multiparticulate Crystalline Drug Compositions Having Controlled Release Profiles
Leah E. Appel - Bend OR, US Roderick J. Ray - Bend OR, US David K. Lyon - Bend OR, US James B. West - Bend OR, US Scott B. McCray - Bend OR, US Marshall D. Crew - Bend OR, US Dwayne T. Friesen - Bend OR, US Scott M. Herbig - East Lyme CT, US Julian B. Lo - Old Lyme CT, US
Assignee:
Pfizer Inc. - New York NY
International Classification:
A61K 9/14 A61K 9/16
US Classification:
424489, 424490
Abstract:
A multiparticulate for controlled release of a drug comprises crystalline drug, a glyceride having at least one alkylate substituent of at least 16 carbon atoms, and a poloxamer, wherein at least 70 wt % of the drug in the multiparticulate is crystalline.
Dwayne T. Friesen - Bend OR, US Marshall D. Crew - Bend OR, US Roderick J. Ray - Bend OR, US Leah E. Appel - Bend OR, US
Assignee:
Pfizer Inc. - New York NY
International Classification:
A61K 9/14 A61K 9/16
US Classification:
424498, 424489
Abstract:
A process for forming drug multiparticulates having improved drug crystallinity is disclosed, comprising modifying a conventional melt-congeal process by adding a volatile cospecies either to the molten mixture or to the process atmosphere, or to both.
Pharmaceutical Compositions Of Drugs And Neutralized Acidic Polymers
Thermo Fisher Scientific
Gvp, Head of Strategy
Patheon
Senior Vice President Innovation
Patheon Mar 2015 - Oct 2016
Vp, Pds Global Science and Technology
Agere Pharmaceuticals Jan 2008 - Mar 2015
President and Chief Executive Officer
Bend Research Jan 1997 - Dec 2007
Vp, Chemical and Biological Sciences
Education:
Oregon State University 1992 - 1997
Doctorates, Doctor of Philosophy
Oregon State University 1992 - 1997
Master of Science, Masters, Physics
University of Idaho 1988 - 1992
Bachelors, Bachelor of Science, Physics
Skills:
Pharmaceutical Industry Technology Transfer R&D Biotechnology Gmp Drug Development Fda Life Sciences Drug Discovery Chemistry Lifesciences Analytical Chemistry Validation Manufacturing Product Development Business Strategy